A real‐world study of adjuvant anti‐PD ‐1 immunotherapy on stage III melanoma with BRAF, NRAS, and KIT mutations

BACKGROUND: Melanoma frequently harbors BRAF, NRAS, or KIT mutations which influence both tumor development and treatment strategies. For example, it is still controversial whether adjuvant anti‐PD‐1 monotherapy or BRAF/MEK inhibitors may better improve the survival for resected BRAF‐mutant melanoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Wei, Xu, Yu, Yan, WangJun, Wang, ChunMeng, Hu, Tu, Luo, ZhiGuo, Zhang, XiaoWei, Liu, Xin, Chen, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469738/
https://www.ncbi.nlm.nih.gov/pubmed/37403699
http://dx.doi.org/10.1002/cam4.6234

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469738/
https://www.ncbi.nlm.nih.gov/pubmed/37403699
http://dx.doi.org/10.1002/cam4.6234

Ejemplares similares